APO Research
Talk to an analyst

APO RESEARCH · REPORT

Imatinib Mesylate API

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Imatinib Mesylate API Market Analysis and Forecast 2026-2032

23 December 2025207 pages

Choose your research edition.

Industry ResearchImatinib Mesylate API Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Imatinib Mesylate API Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Imatinib Mesylate API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Imatinib Mesylate API Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Imatinib Mesylate API Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Imatinib Mesylate API market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Imatinib Mesylate API is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Imatinib Mesylate API is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Imatinib Mesylate API is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Imatinib Mesylate API is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Imatinib Mesylate API include Zhejiang Jiuzhou Pharmaceutical Co Ltd, Sun Pharma, Shanghai Yuanye Bio-Technology, Shandong Anxin Pharmaceutical Co Ltd, Mylan, Zydus Lifesciences Ltd, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd and Shilpa Pharma Lifesciences Ltd, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Imatinib Mesylate API, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Imatinib Mesylate API, also provides the sales of main regions and countries. Of the upcoming market potential for Imatinib Mesylate API, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Imatinib Mesylate API sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Imatinib Mesylate API market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Imatinib Mesylate API sales, projected growth trends, production technology, application and end-user industry.

Imatinib Mesylate API Segment by Company

Zhejiang Jiuzhou Pharmaceutical Co Ltd

Sun Pharma

Shanghai Yuanye Bio-Technology

Shandong Anxin Pharmaceutical Co Ltd

Mylan

Zydus Lifesciences Ltd

Zydus Lifesciences

Sun Pharmaceutical Industries Ltd

Shilpa Pharma Lifesciences Ltd

Natco Pharma Ltd

Msn Laboratories Private Ltd

Laurus Labs Ltd

Intas Pharmaceuticals Ltd

Hetero Labs Ltd

Dr. Reddy’s

Cipla Ltd

Aurobindo Pharma Ltd

Acebright India Pharma Private Ltd

Imatinib Mesylate API Segment by Type

Purity ≥ 98%

Purity < 98%

Imatinib Mesylate API Segment by Application

Chronic Myeloid Leukemia (CML)

Gastrointestinal Stromal Tumor (GIST)

Others

Imatinib Mesylate API Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Imatinib Mesylate API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Imatinib Mesylate API and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Imatinib Mesylate API.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Imatinib Mesylate API in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Imatinib Mesylate API manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Imatinib Mesylate API sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Imatinib Mesylate API Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Purity ≥ 98% Major Manufacturers Table 3. Purity < 98% Major Manufacturers Table 4. Global Imatinib Mesylate API Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Chronic Myeloid Leukemia (CML) Major Manufacturers Table 6. Gastrointestinal Stromal Tumor (GIST) Major Manufacturers Table 7. Others Major Manufacturers Table 8. Imatinib Mesylate API Industry Trends Table 9. Imatinib Mesylate API Industry Drivers Table 10. Imatinib Mesylate API Industry Opportunities and Challenges Table 11. Imatinib Mesylate API Industry Restraints Table 12. Global Imatinib Mesylate API Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Imatinib Mesylate API Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Imatinib Mesylate API Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Imatinib Mesylate API Revenue Market Share by Region (2021-2026) Table 16. Global Imatinib Mesylate API Revenue Market Share by Region (2027-2032) Table 17. Global Imatinib Mesylate API Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (kg) Table 18. Global Imatinib Mesylate API Sales by Region (2021-2026) & (kg) Table 19. Global Imatinib Mesylate API Sales by Region (2027-2032) & (kg) Table 20. Global Imatinib Mesylate API Sales Market Share by Region (2021-2026) Table 21. Global Imatinib Mesylate API Sales Market Share by Region (2027-2032) Table 22. Global Imatinib Mesylate API Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Imatinib Mesylate API Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Imatinib Mesylate API Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Imatinib Mesylate API Sales Market Share by Manufacturers (2021-2026) Table 26. Global Imatinib Mesylate API Sales Price (USD/g) of Manufacturers (2021-2026) Table 27. Global Imatinib Mesylate API Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Imatinib Mesylate API Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Imatinib Mesylate API Manufacturers, Product Type & Application Table 30. Global Imatinib Mesylate API Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Imatinib Mesylate API by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Imatinib Mesylate API Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Imatinib Mesylate API Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Imatinib Mesylate API Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Imatinib Mesylate API Revenue Market Share by Type (2021-2026) Table 37. Global Imatinib Mesylate API Revenue Market Share by Type (2027-2032) Table 38. Global Imatinib Mesylate API Sales by Type 2021 VS 2025 VS 2032 (kg) Table 39. Global Imatinib Mesylate API Sales by Type (2021-2026) & (kg) Table 40. Global Imatinib Mesylate API Sales by Type (2027-2032) & (kg) Table 41. Global Imatinib Mesylate API Sales Market Share by Type (2021-2026) Table 42. Global Imatinib Mesylate API Sales Market Share by Type (2027-2032) Table 43. Global Imatinib Mesylate API Price by Type (2021-2026) & (USD/g) Table 44. Global Imatinib Mesylate API Price by Type (2027-2032) & (USD/g) Table 45. Global Imatinib Mesylate API Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Imatinib Mesylate API Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Imatinib Mesylate API Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Imatinib Mesylate API Revenue Market Share by Application (2021-2026) Table 49. Global Imatinib Mesylate API Revenue Market Share by Application (2027-2032) Table 50. Global Imatinib Mesylate API Sales by Application 2021 VS 2025 VS 2032 (kg) Table 51. Global Imatinib Mesylate API Sales by Application (2021-2026) & (kg) Table 52. Global Imatinib Mesylate API Sales by Application (2027-2032) & (kg) Table 53. Global Imatinib Mesylate API Sales Market Share by Application (2021-2026) Table 54. Global Imatinib Mesylate API Sales Market Share by Application (2027-2032) Table 55. Global Imatinib Mesylate API Price by Application (2021-2026) & (USD/g) Table 56. Global Imatinib Mesylate API Price by Application (2027-2032) & (USD/g) Table 57. Zhejiang Jiuzhou Pharmaceutical Co Ltd Company Information Table 58. Zhejiang Jiuzhou Pharmaceutical Co Ltd Business Overview Table 59. Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 60. Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio Table 61. Zhejiang Jiuzhou Pharmaceutical Co Ltd Recent Development Table 62. Sun Pharma Company Information Table 63. Sun Pharma Business Overview Table 64. Sun Pharma Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 65. Sun Pharma Imatinib Mesylate API Product Portfolio Table 66. Sun Pharma Recent Development Table 67. Shanghai Yuanye Bio-Technology Company Information Table 68. Shanghai Yuanye Bio-Technology Business Overview Table 69. Shanghai Yuanye Bio-Technology Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 70. Shanghai Yuanye Bio-Technology Imatinib Mesylate API Product Portfolio Table 71. Shanghai Yuanye Bio-Technology Recent Development Table 72. Shandong Anxin Pharmaceutical Co Ltd Company Information Table 73. Shandong Anxin Pharmaceutical Co Ltd Business Overview Table 74. Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 75. Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio Table 76. Shandong Anxin Pharmaceutical Co Ltd Recent Development Table 77. Mylan Company Information Table 78. Mylan Business Overview Table 79. Mylan Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 80. Mylan Imatinib Mesylate API Product Portfolio Table 81. Mylan Recent Development Table 82. Zydus Lifesciences Ltd Company Information Table 83. Zydus Lifesciences Ltd Business Overview Table 84. Zydus Lifesciences Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 85. Zydus Lifesciences Ltd Imatinib Mesylate API Product Portfolio Table 86. Zydus Lifesciences Ltd Recent Development Table 87. Zydus Lifesciences Company Information Table 88. Zydus Lifesciences Business Overview Table 89. Zydus Lifesciences Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 90. Zydus Lifesciences Imatinib Mesylate API Product Portfolio Table 91. Zydus Lifesciences Recent Development Table 92. Sun Pharmaceutical Industries Ltd Company Information Table 93. Sun Pharmaceutical Industries Ltd Business Overview Table 94. Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 95. Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Product Portfolio Table 96. Sun Pharmaceutical Industries Ltd Recent Development Table 97. Shilpa Pharma Lifesciences Ltd Company Information Table 98. Shilpa Pharma Lifesciences Ltd Business Overview Table 99. Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 100. Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Product Portfolio Table 101. Shilpa Pharma Lifesciences Ltd Recent Development Table 102. Natco Pharma Ltd Company Information Table 103. Natco Pharma Ltd Business Overview Table 104. Natco Pharma Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 105. Natco Pharma Ltd Imatinib Mesylate API Product Portfolio Table 106. Natco Pharma Ltd Recent Development Table 107. Msn Laboratories Private Ltd Company Information Table 108. Msn Laboratories Private Ltd Business Overview Table 109. Msn Laboratories Private Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 110. Msn Laboratories Private Ltd Imatinib Mesylate API Product Portfolio Table 111. Msn Laboratories Private Ltd Recent Development Table 112. Laurus Labs Ltd Company Information Table 113. Laurus Labs Ltd Business Overview Table 114. Laurus Labs Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 115. Laurus Labs Ltd Imatinib Mesylate API Product Portfolio Table 116. Laurus Labs Ltd Recent Development Table 117. Intas Pharmaceuticals Ltd Company Information Table 118. Intas Pharmaceuticals Ltd Business Overview Table 119. Intas Pharmaceuticals Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 120. Intas Pharmaceuticals Ltd Imatinib Mesylate API Product Portfolio Table 121. Intas Pharmaceuticals Ltd Recent Development Table 122. Hetero Labs Ltd Company Information Table 123. Hetero Labs Ltd Business Overview Table 124. Hetero Labs Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 125. Hetero Labs Ltd Imatinib Mesylate API Product Portfolio Table 126. Hetero Labs Ltd Recent Development Table 127. Dr. Reddy’s Company Information Table 128. Dr. Reddy’s Business Overview Table 129. Dr. Reddy’s Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 130. Dr. Reddy’s Imatinib Mesylate API Product Portfolio Table 131. Dr. Reddy’s Recent Development Table 132. Cipla Ltd Company Information Table 133. Cipla Ltd Business Overview Table 134. Cipla Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 135. Cipla Ltd Imatinib Mesylate API Product Portfolio Table 136. Cipla Ltd Recent Development Table 137. Aurobindo Pharma Ltd Company Information Table 138. Aurobindo Pharma Ltd Business Overview Table 139. Aurobindo Pharma Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 140. Aurobindo Pharma Ltd Imatinib Mesylate API Product Portfolio Table 141. Aurobindo Pharma Ltd Recent Development Table 142. Acebright India Pharma Private Ltd Company Information Table 143. Acebright India Pharma Private Ltd Business Overview Table 144. Acebright India Pharma Private Ltd Imatinib Mesylate API Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 145. Acebright India Pharma Private Ltd Imatinib Mesylate API Product Portfolio Table 146. Acebright India Pharma Private Ltd Recent Development Table 147. North America Imatinib Mesylate API Revenue by Type (2021-2026) & (US$ Million) Table 148. North America Imatinib Mesylate API Revenue by Type (2027-2032) & (US$ Million) Table 149. North America Imatinib Mesylate API Sales by Type (2021-2026) & (kg) Table 150. North America Imatinib Mesylate API Sales by Type (2027-2032) & (kg) Table 151. North America Imatinib Mesylate API Sales Price by Type (2021-2026) & (USD/g) Table 152. North America Imatinib Mesylate API Sales Price by Type (2027-2032) & (USD/g) Table 153. North America Imatinib Mesylate API Revenue by Application (2021-2026) & (US$ Million) Table 154. North America Imatinib Mesylate API Revenue by Application (2027-2032) & (US$ Million) Table 155. North America Imatinib Mesylate API Sales by Application (2021-2026) & (kg) Table 156. North America Imatinib Mesylate API Sales by Application (2027-2032) & (kg) Table 157. North America Imatinib Mesylate API Sales Price by Application (2021-2026) & (USD/g) Table 158. North America Imatinib Mesylate API Sales Price by Application (2027-2032) & (USD/g) Table 159. North America Imatinib Mesylate API Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 160. North America Imatinib Mesylate API Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 161. North America Imatinib Mesylate API Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 162. North America Imatinib Mesylate API Sales by Country (2021 VS 2025 VS 2032) & (kg) Table 163. North America Imatinib Mesylate API Sales by Country (2021-2026) & (kg) Table 164. North America Imatinib Mesylate API Sales by Country (2027-2032) & (kg) Table 165. North America Imatinib Mesylate API Sales Price by Country (2021-2026) & (USD/g) Table 166. North America Imatinib Mesylate API Sales Price by Country (2027-2032) & (USD/g) Table 167. United States Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 168. Canada Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 169. Mexico Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 170. Europe Imatinib Mesylate API Revenue by Type (2021-2026) & (US$ Million) Table 171. Europe Imatinib Mesylate API Revenue by Type (2027-2032) & (US$ Million) Table 172. Europe Imatinib Mesylate API Sales by Type (2021-2026) & (kg) Table 173. Europe Imatinib Mesylate API Sales by Type (2027-2032) & (kg) Table 174. Europe Imatinib Mesylate API Sales Price by Type (2021-2026) & (USD/g) Table 175. Europe Imatinib Mesylate API Sales Price by Type (2027-2032) & (USD/g) Table 176. Europe Imatinib Mesylate API Revenue by Application (2021-2026) & (US$ Million) Table 177. Europe Imatinib Mesylate API Revenue by Application (2027-2032) & (US$ Million) Table 178. Europe Imatinib Mesylate API Sales by Application (2021-2026) & (kg) Table 179. Europe Imatinib Mesylate API Sales by Application (2027-2032) & (kg) Table 180. Europe Imatinib Mesylate API Sales Price by Application (2021-2026) & (USD/g) Table 181. Europe Imatinib Mesylate API Sales Price by Application (2027-2032) & (USD/g) Table 182. Europe Imatinib Mesylate API Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 183. Europe Imatinib Mesylate API Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 184. Europe Imatinib Mesylate API Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 185. Europe Imatinib Mesylate API Sales by Country (2021 VS 2025 VS 2032) & (kg) Table 186. Europe Imatinib Mesylate API Sales by Country (2021-2026) & (kg) Table 187. Europe Imatinib Mesylate API Sales by Country (2027-2032) & (kg) Table 188. Europe Imatinib Mesylate API Sales Price by Country (2021-2026) & (USD/g) Table 189. Europe Imatinib Mesylate API Sales Price by Country (2027-2032) & (USD/g) Table 190. Germany Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 191. France Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 192. U.K. Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 193. Italy Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 194. Russia Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 195. Spain Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 196. Netherlands Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 197. Switzerland Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 198. Sweden Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 199. Poland Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 200. China Imatinib Mesylate API Revenue by Type (2021-2026) & (US$ Million) Table 201. China Imatinib Mesylate API Revenue by Type (2027-2032) & (US$ Million) Table 202. China Imatinib Mesylate API Sales by Type (2021-2026) & (kg) Table 203. China Imatinib Mesylate API Sales by Type (2027-2032) & (kg) Table 204. China Imatinib Mesylate API Sales Price by Type (2021-2026) & (USD/g) Table 205. China Imatinib Mesylate API Sales Price by Type (2027-2032) & (USD/g) Table 206. China Imatinib Mesylate API Revenue by Application (2021-2026) & (US$ Million) Table 207. China Imatinib Mesylate API Revenue by Application (2027-2032) & (US$ Million) Table 208. China Imatinib Mesylate API Sales by Application (2021-2026) & (kg) Table 209. China Imatinib Mesylate API Sales by Application (2027-2032) & (kg) Table 210. China Imatinib Mesylate API Sales Price by Application (2021-2026) & (USD/g) Table 211. China Imatinib Mesylate API Sales Price by Application (2027-2032) & (USD/g) Table 212. Asia Imatinib Mesylate API Revenue by Type (2021-2026) & (US$ Million) Table 213. Asia Imatinib Mesylate API Revenue by Type (2027-2032) & (US$ Million) Table 214. Asia Imatinib Mesylate API Sales by Type (2021-2026) & (kg) Table 215. Asia Imatinib Mesylate API Sales by Type (2027-2032) & (kg) Table 216. Asia Imatinib Mesylate API Sales Price by Type (2021-2026) & (USD/g) Table 217. Asia Imatinib Mesylate API Sales Price by Type (2027-2032) & (USD/g) Table 218. Asia Imatinib Mesylate API Revenue by Application (2021-2026) & (US$ Million) Table 219. Asia Imatinib Mesylate API Revenue by Application (2027-2032) & (US$ Million) Table 220. Asia Imatinib Mesylate API Sales by Application (2021-2026) & (kg) Table 221. Asia Imatinib Mesylate API Sales by Application (2027-2032) & (kg) Table 222. Asia Imatinib Mesylate API Sales Price by Application (2021-2026) & (USD/g) Table 223. Asia Imatinib Mesylate API Sales Price by Application (2027-2032) & (USD/g) Table 224. Asia Imatinib Mesylate API Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 225. Asia Imatinib Mesylate API Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 226. Asia Imatinib Mesylate API Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 227. Asia Imatinib Mesylate API Sales by Country (2021 VS 2025 VS 2032) & (kg) Table 228. Asia Imatinib Mesylate API Sales by Country (2021-2026) & (kg) Table 229. Asia Imatinib Mesylate API Sales by Country (2027-2032) & (kg) Table 230. Asia Imatinib Mesylate API Sales Price by Country (2021-2026) & (USD/g) Table 231. Asia Imatinib Mesylate API Sales Price by Country (2027-2032) & (USD/g) Table 232. Japan Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 233. South Korea Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 234. India Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 235. Australia Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 236. Taiwan Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 237. Southeast Asia Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 238. SAMEA Imatinib Mesylate API Revenue by Type (2021-2026) & (US$ Million) Table 239. SAMEA Imatinib Mesylate API Revenue by Type (2027-2032) & (US$ Million) Table 240. SAMEA Imatinib Mesylate API Sales by Type (2021-2026) & (kg) Table 241. SAMEA Imatinib Mesylate API Sales by Type (2027-2032) & (kg) Table 242. SAMEA Imatinib Mesylate API Sales Price by Type (2021-2026) & (USD/g) Table 243. SAMEA Imatinib Mesylate API Sales Price by Type (2027-2032) & (USD/g) Table 244. SAMEA Imatinib Mesylate API Revenue by Application (2021-2026) & (US$ Million) Table 245. SAMEA Imatinib Mesylate API Revenue by Application (2027-2032) & (US$ Million) Table 246. SAMEA Imatinib Mesylate API Sales by Application (2021-2026) & (kg) Table 247. SAMEA Imatinib Mesylate API Sales by Application (2027-2032) & (kg) Table 248. SAMEA Imatinib Mesylate API Sales Price by Application (2021-2026) & (USD/g) Table 249. SAMEA Imatinib Mesylate API Sales Price by Application (2027-2032) & (USD/g) Table 250. SAMEA Imatinib Mesylate API Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 251. SAMEA Imatinib Mesylate API Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 252. SAMEA Imatinib Mesylate API Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 253. SAMEA Imatinib Mesylate API Sales by Country (2021 VS 2025 VS 2032) & (kg) Table 254. SAMEA Imatinib Mesylate API Sales by Country (2021-2026) & (kg) Table 255. SAMEA Imatinib Mesylate API Sales by Country (2027-2032) & (kg) Table 256. SAMEA Imatinib Mesylate API Sales Price by Country (2021-2026) & (USD/g) Table 257. SAMEA Imatinib Mesylate API Sales Price by Country (2027-2032) & (USD/g) Table 258. Brazil Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 259. Argentina Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 260. Chile Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 261. Colombia Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 262. Peru Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 263. Saudi Arabia Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 264. Israel Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 265. UAE Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 266. Turkey Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 267. Iran Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 268. Egypt Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Table 269. Key Raw Materials Table 270. Raw Materials Key Suppliers Table 271. Imatinib Mesylate API Distributors List Table 272. Imatinib Mesylate API Customers List Table 273. Research Programs/Design for This Report Table 274. Authors List of This Report Table 275. Secondary Sources Table 276. Primary Sources List of Figures Figure 1. Imatinib Mesylate API Image Figure 2. Global Imatinib Mesylate API Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Imatinib Mesylate API Market Size Share 2021 VS 2025 VS 2032 Figure 4. Purity ≥ 98% Image Figure 5. Purity < 98% Image Figure 6. Global Imatinib Mesylate API Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Imatinib Mesylate API Market Size Share 2021 VS 2025 VS 2032 Figure 8. Chronic Myeloid Leukemia (CML) Image Figure 9. Gastrointestinal Stromal Tumor (GIST) Image Figure 10. Others Image Figure 11. Global Imatinib Mesylate API Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Imatinib Mesylate API Revenue (2021-2032) & (US$ Million) Figure 13. Global Imatinib Mesylate API Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Imatinib Mesylate API Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Imatinib Mesylate API Revenue Market Share by Region (2021-2032) Figure 16. Global Imatinib Mesylate API Sales (2021-2032) & (kg) Figure 17. Global Imatinib Mesylate API Sales by Region: 2021 VS 2025 VS 2032 (kg) Figure 18. Global Imatinib Mesylate API Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Imatinib Mesylate API Sales YoY (2021-2032) & (kg) Figure 20. Europe Imatinib Mesylate API Sales YoY (2021-2032) & (kg) Figure 21. China Imatinib Mesylate API Sales YoY (2021-2032) & (kg) Figure 22. Asia (Excluding China) Imatinib Mesylate API Sales YoY (2021-2032) & (kg) Figure 23. South America, Middle East and Africa Imatinib Mesylate API Sales YoY (2021-2032) & (kg) Figure 24. Global Imatinib Mesylate API Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Imatinib Mesylate API Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Imatinib Mesylate API Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Imatinib Mesylate API Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Imatinib Mesylate API Revenue Market Share by Type (2021-2032) Figure 30. Global Imatinib Mesylate API Sales by Type (2021 VS 2025 VS 2032) & (kg) Figure 31. Global Imatinib Mesylate API Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Imatinib Mesylate API Sales Market Share by Type (2021-2032) Figure 33. Global Imatinib Mesylate API Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Imatinib Mesylate API Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Imatinib Mesylate API Revenue Market Share by Application (2021-2032) Figure 36. Global Imatinib Mesylate API Sales by Application (2021 VS 2025 VS 2032) & (kg) Figure 37. Global Imatinib Mesylate API Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Imatinib Mesylate API Sales Market Share by Application (2021-2032) Figure 39. North America Imatinib Mesylate API Revenue Share by Type (2021-2032) Figure 40. North America Imatinib Mesylate API Sales Share by Type (2021-2032) Figure 41. North America Imatinib Mesylate API Revenue Share by Application (2021-2032) Figure 42. North America Imatinib Mesylate API Sales Share by Application (2021-2032) Figure 43. North America Imatinib Mesylate API Revenue Share by Country (2021-2032) Figure 44. North America Imatinib Mesylate API Sales Share by Country (2021-2032) Figure 45. Europe Imatinib Mesylate API Revenue Share by Type (2021-2032) Figure 46. Europe Imatinib Mesylate API Sales Share by Type (2021-2032) Figure 47. Europe Imatinib Mesylate API Revenue Share by Application (2021-2032) Figure 48. Europe Imatinib Mesylate API Sales Share by Application (2021-2032) Figure 49. Europe Imatinib Mesylate API Revenue Share by Country (2021-2032) Figure 50. Europe Imatinib Mesylate API Sales Share by Country (2021-2032) Figure 51. China Imatinib Mesylate API Revenue Share by Type (2021-2032) Figure 52. China Imatinib Mesylate API Sales Share by Type (2021-2032) Figure 53. China Imatinib Mesylate API Revenue Share by Application (2021-2032) Figure 54. China Imatinib Mesylate API Sales Share by Application (2021-2032) Figure 55. Asia Imatinib Mesylate API Revenue Share by Type (2021-2032) Figure 56. Asia Imatinib Mesylate API Sales Share by Type (2021-2032) Figure 57. Asia Imatinib Mesylate API Revenue Share by Application (2021-2032) Figure 58. Asia Imatinib Mesylate API Sales Share by Application (2021-2032) Figure 59. Asia Imatinib Mesylate API Revenue Share by Country (2021-2032) Figure 60. Asia Imatinib Mesylate API Sales Share by Country (2021-2032) Figure 61. SAMEA Imatinib Mesylate API Revenue Share by Type (2021-2032) Figure 62. SAMEA Imatinib Mesylate API Sales Share by Type (2021-2032) Figure 63. SAMEA Imatinib Mesylate API Revenue Share by Application (2021-2032) Figure 64. SAMEA Imatinib Mesylate API Sales Share by Application (2021-2032) Figure 65. SAMEA Imatinib Mesylate API Revenue Share by Country (2021-2032) Figure 66. SAMEA Imatinib Mesylate API Sales Share by Country (2021-2032) Figure 67. Imatinib Mesylate API Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Imatinib Mesylate API Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Purity ≥ 98%
  • Purity < 98%
Applications
  • Chronic Myeloid Leukemia (CML)
  • Gastrointestinal Stromal Tumor (GIST)
  • Others
Companies covered
  • Zhejiang Jiuzhou Pharmaceutical Co Ltd
  • Sun Pharma
  • Shanghai Yuanye Bio-Technology
  • Shandong Anxin Pharmaceutical Co Ltd
  • Mylan
  • Zydus Lifesciences Ltd
  • Zydus Lifesciences
  • Sun Pharmaceutical Industries Ltd
  • Shilpa Pharma Lifesciences Ltd
  • Natco Pharma Ltd
  • Msn Laboratories Private Ltd
  • Laurus Labs Ltd
  • Intas Pharmaceuticals Ltd
  • Hetero Labs Ltd
  • Dr. Reddy’s
  • Cipla Ltd
  • Aurobindo Pharma Ltd
  • Acebright India Pharma Private Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Imatinib Mesylate API Market by Type
  3. 1.2.1 Global Imatinib Mesylate API Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Purity ≥ 98%
  5. 1.2.3 Purity < 98%
  6. 1.3 Imatinib Mesylate API Market by Application
  7. 1.3.1 Global Imatinib Mesylate API Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Chronic Myeloid Leukemia (CML)
  9. 1.3.3 Gastrointestinal Stromal Tumor (GIST)
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Imatinib Mesylate API Market Dynamics
  1. 2.1 Imatinib Mesylate API Industry Trends
  2. 2.2 Imatinib Mesylate API Industry Drivers
  3. 2.3 Imatinib Mesylate API Industry Opportunities and Challenges
  4. 2.4 Imatinib Mesylate API Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Imatinib Mesylate API Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Imatinib Mesylate API Revenue by Region
  3. 3.2.1 Global Imatinib Mesylate API Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Imatinib Mesylate API Revenue by Region (2021-2026)
  5. 3.2.3 Global Imatinib Mesylate API Revenue by Region (2027-2032)
  6. 3.2.4 Global Imatinib Mesylate API Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Imatinib Mesylate API Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Imatinib Mesylate API Sales by Region
  9. 3.4.1 Global Imatinib Mesylate API Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Imatinib Mesylate API Sales by Region (2021-2026)
  11. 3.4.3 Global Imatinib Mesylate API Sales by Region (2027-2032)
  12. 3.4.4 Global Imatinib Mesylate API Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Imatinib Mesylate API Revenue by Manufacturers
  2. 4.1.1 Global Imatinib Mesylate API Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Imatinib Mesylate API Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Imatinib Mesylate API Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Imatinib Mesylate API Sales by Manufacturers
  6. 4.2.1 Global Imatinib Mesylate API Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Imatinib Mesylate API Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Imatinib Mesylate API Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Imatinib Mesylate API Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Imatinib Mesylate API Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Imatinib Mesylate API Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Imatinib Mesylate API Manufacturers, Product Type & Application
  13. 4.7 Global Imatinib Mesylate API Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Imatinib Mesylate API Market CR5 and HHI
  16. 4.8.2 2025 Imatinib Mesylate API Tier 1, Tier 2, and Tier 3
5 Imatinib Mesylate API Market by Type
  1. 5.1 Global Imatinib Mesylate API Revenue by Type
  2. 5.1.1 Global Imatinib Mesylate API Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Imatinib Mesylate API Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Imatinib Mesylate API Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Imatinib Mesylate API Sales by Type
  6. 5.2.1 Global Imatinib Mesylate API Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Imatinib Mesylate API Sales by Type (2021-2032) & (kg)
  8. 5.2.3 Global Imatinib Mesylate API Sales Market Share by Type (2021-2032)
  9. 5.3 Global Imatinib Mesylate API Price by Type
6 Imatinib Mesylate API Market by Application
  1. 6.1 Global Imatinib Mesylate API Revenue by Application
  2. 6.1.1 Global Imatinib Mesylate API Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Imatinib Mesylate API Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Imatinib Mesylate API Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Imatinib Mesylate API Sales by Application
  6. 6.2.1 Global Imatinib Mesylate API Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Imatinib Mesylate API Sales by Application (2021-2032) & (kg)
  8. 6.2.3 Global Imatinib Mesylate API Sales Market Share by Application (2021-2032)
  9. 6.3 Global Imatinib Mesylate API Price by Application
7 Company Profiles
  1. 7.1 Zhejiang Jiuzhou Pharmaceutical Co Ltd
  2. 7.1.1 Zhejiang Jiuzhou Pharmaceutical Co Ltd Company Information
  3. 7.1.2 Zhejiang Jiuzhou Pharmaceutical Co Ltd Business Overview
  4. 7.1.3 Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio
  6. 7.1.5 Zhejiang Jiuzhou Pharmaceutical Co Ltd Recent Developments
  7. 7.2 Sun Pharma
  8. 7.2.1 Sun Pharma Company Information
  9. 7.2.2 Sun Pharma Business Overview
  10. 7.2.3 Sun Pharma Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sun Pharma Imatinib Mesylate API Product Portfolio
  12. 7.2.5 Sun Pharma Recent Developments
  13. 7.3 Shanghai Yuanye Bio-Technology
  14. 7.3.1 Shanghai Yuanye Bio-Technology Company Information
  15. 7.3.2 Shanghai Yuanye Bio-Technology Business Overview
  16. 7.3.3 Shanghai Yuanye Bio-Technology Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Shanghai Yuanye Bio-Technology Imatinib Mesylate API Product Portfolio
  18. 7.3.5 Shanghai Yuanye Bio-Technology Recent Developments
  19. 7.4 Shandong Anxin Pharmaceutical Co Ltd
  20. 7.4.1 Shandong Anxin Pharmaceutical Co Ltd Company Information
  21. 7.4.2 Shandong Anxin Pharmaceutical Co Ltd Business Overview
  22. 7.4.3 Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio
  24. 7.4.5 Shandong Anxin Pharmaceutical Co Ltd Recent Developments
  25. 7.5 Mylan
  26. 7.5.1 Mylan Company Information
  27. 7.5.2 Mylan Business Overview
  28. 7.5.3 Mylan Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Mylan Imatinib Mesylate API Product Portfolio
  30. 7.5.5 Mylan Recent Developments
  31. 7.6 Zydus Lifesciences Ltd
  32. 7.6.1 Zydus Lifesciences Ltd Company Information
  33. 7.6.2 Zydus Lifesciences Ltd Business Overview
  34. 7.6.3 Zydus Lifesciences Ltd Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Zydus Lifesciences Ltd Imatinib Mesylate API Product Portfolio
  36. 7.6.5 Zydus Lifesciences Ltd Recent Developments
  37. 7.7 Zydus Lifesciences
  38. 7.7.1 Zydus Lifesciences Company Information
  39. 7.7.2 Zydus Lifesciences Business Overview
  40. 7.7.3 Zydus Lifesciences Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Zydus Lifesciences Imatinib Mesylate API Product Portfolio
  42. 7.7.5 Zydus Lifesciences Recent Developments
  43. 7.8 Sun Pharmaceutical Industries Ltd
  44. 7.8.1 Sun Pharmaceutical Industries Ltd Company Information
  45. 7.8.2 Sun Pharmaceutical Industries Ltd Business Overview
  46. 7.8.3 Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Product Portfolio
  48. 7.8.5 Sun Pharmaceutical Industries Ltd Recent Developments
  49. 7.9 Shilpa Pharma Lifesciences Ltd
  50. 7.9.1 Shilpa Pharma Lifesciences Ltd Company Information
  51. 7.9.2 Shilpa Pharma Lifesciences Ltd Business Overview
  52. 7.9.3 Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Product Portfolio
  54. 7.9.5 Shilpa Pharma Lifesciences Ltd Recent Developments
  55. 7.10 Natco Pharma Ltd
  56. 7.10.1 Natco Pharma Ltd Company Information
  57. 7.10.2 Natco Pharma Ltd Business Overview
  58. 7.10.3 Natco Pharma Ltd Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Natco Pharma Ltd Imatinib Mesylate API Product Portfolio
  60. 7.10.5 Natco Pharma Ltd Recent Developments
  61. 7.11 Msn Laboratories Private Ltd
  62. 7.11.1 Msn Laboratories Private Ltd Company Information
  63. 7.11.2 Msn Laboratories Private Ltd Business Overview
  64. 7.11.3 Msn Laboratories Private Ltd Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Msn Laboratories Private Ltd Imatinib Mesylate API Product Portfolio
  66. 7.11.5 Msn Laboratories Private Ltd Recent Developments
  67. 7.12 Laurus Labs Ltd
  68. 7.12.1 Laurus Labs Ltd Company Information
  69. 7.12.2 Laurus Labs Ltd Business Overview
  70. 7.12.3 Laurus Labs Ltd Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Laurus Labs Ltd Imatinib Mesylate API Product Portfolio
  72. 7.12.5 Laurus Labs Ltd Recent Developments
  73. 7.13 Intas Pharmaceuticals Ltd
  74. 7.13.1 Intas Pharmaceuticals Ltd Company Information
  75. 7.13.2 Intas Pharmaceuticals Ltd Business Overview
  76. 7.13.3 Intas Pharmaceuticals Ltd Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Intas Pharmaceuticals Ltd Imatinib Mesylate API Product Portfolio
  78. 7.13.5 Intas Pharmaceuticals Ltd Recent Developments
  79. 7.14 Hetero Labs Ltd
  80. 7.14.1 Hetero Labs Ltd Company Information
  81. 7.14.2 Hetero Labs Ltd Business Overview
  82. 7.14.3 Hetero Labs Ltd Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Hetero Labs Ltd Imatinib Mesylate API Product Portfolio
  84. 7.14.5 Hetero Labs Ltd Recent Developments
  85. 7.15 Dr. Reddy’s
  86. 7.15.1 Dr. Reddy’s Company Information
  87. 7.15.2 Dr. Reddy’s Business Overview
  88. 7.15.3 Dr. Reddy’s Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Dr. Reddy’s Imatinib Mesylate API Product Portfolio
  90. 7.15.5 Dr. Reddy’s Recent Developments
  91. 7.16 Cipla Ltd
  92. 7.16.1 Cipla Ltd Company Information
  93. 7.16.2 Cipla Ltd Business Overview
  94. 7.16.3 Cipla Ltd Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Cipla Ltd Imatinib Mesylate API Product Portfolio
  96. 7.16.5 Cipla Ltd Recent Developments
  97. 7.17 Aurobindo Pharma Ltd
  98. 7.17.1 Aurobindo Pharma Ltd Company Information
  99. 7.17.2 Aurobindo Pharma Ltd Business Overview
  100. 7.17.3 Aurobindo Pharma Ltd Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Aurobindo Pharma Ltd Imatinib Mesylate API Product Portfolio
  102. 7.17.5 Aurobindo Pharma Ltd Recent Developments
  103. 7.18 Acebright India Pharma Private Ltd
  104. 7.18.1 Acebright India Pharma Private Ltd Company Information
  105. 7.18.2 Acebright India Pharma Private Ltd Business Overview
  106. 7.18.3 Acebright India Pharma Private Ltd Imatinib Mesylate API Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Acebright India Pharma Private Ltd Imatinib Mesylate API Product Portfolio
  108. 7.18.5 Acebright India Pharma Private Ltd Recent Developments
8 North America
  1. 8.1 North America Imatinib Mesylate API Market Size by Type
  2. 8.1.1 North America Imatinib Mesylate API Revenue by Type (2021-2032)
  3. 8.1.2 North America Imatinib Mesylate API Sales by Type (2021-2032)
  4. 8.1.3 North America Imatinib Mesylate API Price by Type (2021-2032)
  5. 8.2 North America Imatinib Mesylate API Market Size by Application
  6. 8.2.1 North America Imatinib Mesylate API Revenue by Application (2021-2032)
  7. 8.2.2 North America Imatinib Mesylate API Sales by Application (2021-2032)
  8. 8.2.3 North America Imatinib Mesylate API Price by Application (2021-2032)
  9. 8.3 North America Imatinib Mesylate API Market Size by Country
  10. 8.3.1 North America Imatinib Mesylate API Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Imatinib Mesylate API Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Imatinib Mesylate API Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Imatinib Mesylate API Market Size by Type
  2. 9.1.1 Europe Imatinib Mesylate API Revenue by Type (2021-2032)
  3. 9.1.2 Europe Imatinib Mesylate API Sales by Type (2021-2032)
  4. 9.1.3 Europe Imatinib Mesylate API Price by Type (2021-2032)
  5. 9.2 Europe Imatinib Mesylate API Market Size by Application
  6. 9.2.1 Europe Imatinib Mesylate API Revenue by Application (2021-2032)
  7. 9.2.2 Europe Imatinib Mesylate API Sales by Application (2021-2032)
  8. 9.2.3 Europe Imatinib Mesylate API Price by Application (2021-2032)
  9. 9.3 Europe Imatinib Mesylate API Market Size by Country
  10. 9.3.1 Europe Imatinib Mesylate API Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Imatinib Mesylate API Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Imatinib Mesylate API Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Imatinib Mesylate API Market Size by Type
  2. 10.1.1 China Imatinib Mesylate API Revenue by Type (2021-2032)
  3. 10.1.2 China Imatinib Mesylate API Sales by Type (2021-2032)
  4. 10.1.3 China Imatinib Mesylate API Price by Type (2021-2032)
  5. 10.2 China Imatinib Mesylate API Market Size by Application
  6. 10.2.1 China Imatinib Mesylate API Revenue by Application (2021-2032)
  7. 10.2.2 China Imatinib Mesylate API Sales by Application (2021-2032)
  8. 10.2.3 China Imatinib Mesylate API Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Imatinib Mesylate API Market Size by Type
  2. 11.1.1 Asia Imatinib Mesylate API Revenue by Type (2021-2032)
  3. 11.1.2 Asia Imatinib Mesylate API Sales by Type (2021-2032)
  4. 11.1.3 Asia Imatinib Mesylate API Price by Type (2021-2032)
  5. 11.2 Asia Imatinib Mesylate API Market Size by Application
  6. 11.2.1 Asia Imatinib Mesylate API Revenue by Application (2021-2032)
  7. 11.2.2 Asia Imatinib Mesylate API Sales by Application (2021-2032)
  8. 11.2.3 Asia Imatinib Mesylate API Price by Application (2021-2032)
  9. 11.3 Asia Imatinib Mesylate API Market Size by Country
  10. 11.3.1 Asia Imatinib Mesylate API Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Imatinib Mesylate API Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Imatinib Mesylate API Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Imatinib Mesylate API Market Size by Type
  2. 12.1.1 SAMEA Imatinib Mesylate API Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Imatinib Mesylate API Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Imatinib Mesylate API Price by Type (2021-2032)
  5. 12.2 SAMEA Imatinib Mesylate API Market Size by Application
  6. 12.2.1 SAMEA Imatinib Mesylate API Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Imatinib Mesylate API Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Imatinib Mesylate API Price by Application (2021-2032)
  9. 12.3 SAMEA Imatinib Mesylate API Market Size by Country
  10. 12.3.1 SAMEA Imatinib Mesylate API Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Imatinib Mesylate API Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Imatinib Mesylate API Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Imatinib Mesylate API Value Chain Analysis
  2. 13.1.1 Imatinib Mesylate API Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Imatinib Mesylate API Production Mode & Process
  6. 13.2 Imatinib Mesylate API Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Imatinib Mesylate API Distributors
  9. 13.2.3 Imatinib Mesylate API Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst